Published in Gene Therapy Weekly, January 6th, 2005
Stagner will be responsible for management of the company's project development teams and programs.
"Stagner is an outstanding pharmaceutical executive who brings to POZEN years of experience in the management of pharmaceutics, preclinical, and clinical development programs, as well as experience as a general manager," said Dr. John R. Plachetka, POZEN's chairman, president, and chief executive officer.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly